Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $30M fell 24.8% year over year, behind the -11.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 19.5% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.
Context
- Stock-based compensation amounted to 22.7% of revenue in FY2025, down 5.5 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -24.8% toward the trailing-twelve-month pace of -11.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 153M USD
- Year-over-year change
- -3.2%
- 4-year CAGR
- +9.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 153M | -3.2% |
| FY2024 | 2024-12-31 | 158.03M | +16.9% |
| FY2023 | 2023-12-31 | 135.21M | +3.7% |
| FY2022 | 2022-12-31 | 130.38M | +24.2% |
| FY2021 | 2021-12-31 | 104.95M | — |
Stock-Based Compensation vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 stock-based compensation of $142.83M is the 2nd largest of the 11 companies compared; the peer median is $34.93M.
- Its year-over-year change of -11.3% is the 9th highest of 11, against a peer median of -6.4%.
- Stock-based compensation amounts to 21.3% of revenue for RARE, versus a peer median of 39.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $172.73B | +92559.3% | -2.6% | 16.8% | |
| LTM Mar 2026 | $142.83M | -11.3% | +5.5% | 21.3% | |
| LTM Jun 2026 | $111.95M | -7.0% | +13.3% | 15.7% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Mar 2026 | $47.93M | +107.3% | -8.3% | 60.1% | |
| LTM Mar 2026 | $35.22M | -20.0% | +6.1% | — | |
| LTM Mar 2026 | $34.64M | -7.4% | -5.4% | 39.4% | |
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Mar 2026 | $18.36M | -5.7% | -19.7% | 101.5% | |
| LTM Mar 2026 | $8.33M | +7.1% | +52.3% | 57.3% | |
| LTM Mar 2026 | $6.93M | -9.1% | +16.8% | 1385.0% | |
| Peer median (excluding RARE) | $34.93M | -6.4% | +1.8% | 39.4% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| Deferred Income Tax | 48.67M | 0 | (1.62M) | 0 | 0 |
| Stock-Based Compensation | 104.95M | 130.38M | 135.21M | 158.03M | 153M |
| Change in Working Capital | (63.24M) | 60.24M | (15.1M) | 13.92M | (23M) |
| Accounts Receivables | (5.43M) | (12.07M) | (22.78M) | (33.6M) | (31M) |
| Inventory | (3.12M) | (9.7M) | (6.93M) | (11.21M) | (6M) |
| Accounts Payables | 2.81M | 79.85M | 2.38M | 46.99M | 24M |
| Other Working Capital | (57.49M) | 2.16M | 12.23M | 11.73M | (10M) |
| Other Non-Cash Items | 11.71M | 118.12M | (12.67M) | (52.5M) | (56M) |
| Operating Cash Flow | (338.7M) | (380.47M) | (474.81M) | (414.19M) | (466M) |
| Capital Expenditures | (73.09M) | (146.12M) | (46.77M) | (7.49M) | (6M) |
| Acquisitions (Net) | 0 | (75.03M) | 0 | 0 | 0 |
| Purchases of Investments | (1.01B) | (614.74M) | (526.38M) | (408.61M) | (186M) |
| Sales of Investments | 890.85M | 545.08M | 746.2M | 413.27M | 444M |
| Other Investing Activities | (942K) | (30.84M) | (7.55M) | (14.94M) | (16M) |
| Investing Cash Flow | (195.37M) | (291.65M) | 168M | (17.77M) | 236M |
| Debt Repayment | 0 | 0 | 0 | 0 | 392M |
| Common Stock Issued | 78.94M | 0 | 379.76M | 380.98M | 86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 39.61M | 501.21M | 8.39M | 18.26M | 0 |
| Financing Cash Flow | 118.55M | 501.21M | 388.14M | 399.24M | 478M |
| Effect of Forex Changes | (1.19M) | (1.08M) | 462K | (2.53M) | 5.47M |
| Net Change in Cash | (416.71M) | (171.98M) | 81.8M | (35.24M) | 253.47M |
| Free Cash Flow | (411.79M) | (526.59M) | (521.57M) | (421.68M) | (472M) |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.